Neuphoria Therapeutics Inc.
Financial highlights
| Metric | FY June 30, 2025 | FY June 30, 2024 | FY June 30, 2023 |
|---|---|---|---|
| Revenue | $15.6M | — | — |
| Operating income | -$1.1M | -$17.9M | -$22.0M |
| Operating expenses | $16.8M | $17.9M | $22.0M |
| Cash from operations | $77,229 | -$14.7M | -$14.6M |
| Impairments | $0 | $0 | — |
| Total assets | $28.6M | $27.6M | $28.6M |
| Total liabilities | $9.6M | $10.2M | $6.6M |
Shares outstanding 5.4M · Free float 79.0%
Annual filing data through FY ended June 30, 2025; float as of July 12, 2026.